Solid Biosciences Inc. SLDB Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -109.9%-15.3pp | -94.6%-37.8pp | -56.8%-15.8pp | -41%+1.5pp | |
| Return on assets | -82.8%-12.2pp | -70.5%-25.4pp | -45.2%-10.3pp | -34.9%+0.9pp | |
| Return on invested capital | -161.1%+1.1pp | -162.2%-34.8pp | -127.5%-6.6pp | -120.8%— | |
| Liquidity | |||||
| Current ratio | 6.1×+0.9× | 5.2×-3.7× | 8.9×-0.8× | 9.8×+0.3× | |
| Quick ratio | 6.1×+0.9× | 5.2×-3.7× | 8.9×-0.8× | 9.8×+0.3× | |
| Cash ratio | 1.8×-0.9× | 2.7×-2.4× | 5.1×-1.8× | 6.9×+1.9× | |
| Leverage | |||||
| Debt-to-equity | 0.1×-0.1× | 0.2×0.0× | 0.2×+0.1× | 0.1×+0.1× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.2×0.0× | 0.1×+0.1× | |
| Per Share | |||||
| Book value per share | $2.06-38.8% | $3.36-47.1% | $6.36-74.4% | $24.87-15.0% | |
| Valuation | |||||
| Market capitalization | $910.66M+135% | $159.82M+29.0% | $123.89M+17.9% | $105.06M-45.6% | |
| Enterprise value | $634.23M+223% | $103.76M+36.3% | $76.14M+450% | -$21.78M-129% | |
| Price / book | 2.3×+1.1× | 1.2×+0.2× | 1×+0.5× | 0.5×-0.4× | |
| Free cash flow yield | -19.8%+9.1pp | -63%+14.3pp | -77.2%+18.9pp | -96.1%-55.2pp | |
| Earnings yield | -22%+15.6pp | -78%-0.5pp | -77.5%+4.3pp | -81.8%-44.4pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Solid Biosciences Inc.'s ratios come from?
- Every ratio is computed from Solid Biosciences Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
